Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky

Sponsor
Hilary L Surratt, PhD (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05037513
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
80
1
2
28.5
2.8

Study Details

Study Description

Brief Summary

The overarching goal of this study is to adapt and feasibility test an evidence-based strengths-based case management (SBCM) intervention for pre-exposure prophylaxis (PrEP) initiation, and examine preliminary efficacy of the intervention comparators (SBCM-PrEP) and (Centers for Disease Control (CDC)-PrEP). Within this context, the Specific Aims are to: 1) Assess client, provider, organization, and structural-level facilitators and barriers to integration of a PrEP focused SBCM (SBCM-PrEP) intervention into routine syringe service program (SSP) practice; 2) Adapt an evidence-based SBCM protocol to provide PrEP intervention services for people who inject drugs (PWID) in SSP sites; and, 3) Examine feasibility, acceptability and preliminary efficacy of the adapted SBCM-PrEP. 80 participants will be randomized into: CDC-PrEP (an in-use PrEP intervention based on CDC guidelines) or SBCM-PrEP.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: SBCM-PrEP
  • Behavioral: CDC-PrEP
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
Actual Study Start Date :
Sep 16, 2021
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: CDC-PrEP

1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting

Behavioral: CDC-PrEP
1 session PrEP education following CDC guidelines

Experimental: SBCM-PrEP

Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting

Behavioral: SBCM-PrEP
Multi-session SBCM intervention adapted for PrEP initiation focus

Outcome Measures

Primary Outcome Measures

  1. Number of participants initiating PrEP [3 months post-baseline]

    Documented PrEP initiation, measured by dispensed PrEP prescription.

  2. Number of participants initiating PrEP [6 months post-baseline]

    Documented PrEP initiation, measured by dispensed PrEP prescription.

Secondary Outcome Measures

  1. Level of Intervention Engagement assessed by session checklist [8 weeks post-baseline]

    5 item Session Checklist completed by Nurse-Interventionist post-session; range is 0-15, higher scores are higher engagement

  2. Level of Intervention Satisfaction assessed by the IAQ [8 weeks post-baseline]

    8 item Intervention Acceptability Questionnaire (IAQ) completed by participants post-intervention; range is 0-32, higher scores are higher satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 years or older;

  • HIV-negative status;

  • Past month drug injection;

  • Client of SSP in targeted sites

Exclusion Criteria:

• HIV-positive status

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Kentucky Lexington Kentucky United States 40536

Sponsors and Collaborators

  • Hilary L Surratt, PhD
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Hilary L Surratt, PhD, University of Kentucky

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hilary L Surratt, PhD, Associate Professor, University of Kentucky
ClinicalTrials.gov Identifier:
NCT05037513
Other Study ID Numbers:
  • 67933
  • R34DA053140
First Posted:
Sep 8, 2021
Last Update Posted:
Oct 5, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Oct 5, 2021